VP of Finance, Accounting and Administration

Chief Scientific Officer

CG Oncology price target raised by $23 at Morgan Stanley, here's why

CG Oncology Insider Bought Shares Worth $49,999,983, According to a Recent SEC Filing

CG Oncology announces updated data on BOND-003 Cohort C

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

Director, Biostatistics

CG Oncology, Inc. is focused on advancing treatments for bladder cancer through innovative immunotherapies. They are seeking a Director of Biostatistics to lead statistical strategy and execution for clinical programs, particularly for their lead candidate, Cretostimogene grenadenorepvec, while ensuring compliance with regulatory standards and contributing to evidence generation strategies.

Sign up with Google

Sign in with Google